Alector announces completion of enrollment in the progress-ad phase 2 clinical trial of al101/gsk4527226 in individuals with early alzheimer's disease

--76-week trial is evaluating the safety and efficacy of a progranulin-elevating candidate in slowing disease progression-- --enrollment completed ahead of schedule-- south san francisco, calif., april 17, 2025 (globe newswire) -- alector, inc. (nasdaq: alec), a late-stage clinical biotechnology company focused on developing therapies to counteract the devastating progression of neurodegeneration, today announced the completion of enrollment in progress-ad, a 76-week phase 2 clinical trial evaluating the safety and efficacy of al101/gsk4527226 in slowing disease progression in individuals with early alzheimer's disease (ad).
ALEC Ratings Summary
ALEC Quant Ranking